Condition: ATTR Amyloidosis · Sponsor: AstraZeneca
The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns and selected clinical, economic, and humanistic outcomes (for example Health Related Quality of Life (HRQoL), Neuropathy impairment score, activities of daily living (ADL) assessments) in patients with ATTR amyloidosis, and to better understand how the disease is presented.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Eden Prairie, Minnesota, United States | Completed |
| Research Site | Calgary, Alberta, Canada | Completed |
| Research Site | Beijing, China | Completed |
| Research Site | Changsha, China | Completed |
| Research Site | Chengdu, China | Completed |
| Research Site | Guangzhou, China | Completed |
| Research Site | Wuhan, China | Completed |
| Research Site | Horsens, Denmark | Completed |
| Research Site | Berlin, Germany | Completed |
| Research Site | Lecce, Italy | Not Yet Recruiting |
| Research Site | Messina, Italy | Not Yet Recruiting |
| Research Site | Milan, Italy | Not Yet Recruiting |
+ 17 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06355934